High-sensitive and multiplex biosensing assay of NSCLC-derived exosomes via different recognition sites based on SPRi array.

Non-small cell lung cancer (NSCLC) have been reported to secret a high concentration of exosomes into blood circulatory system, which is one of sensitive and non-invasive biomarkers for NSCLC's early-stage diagnosis. But it is still lack of feasible and accurate methods to analyze the different NSCLC cells-derived exosomes. Herein, we built a SPRi biosensing assay for high-sensitive and multiplex characterizations of NSCLC-derived exosomes by bioaffinity interactions of antibodies and different recognition sites. By this way, the exosomes derived from normal lung and NSCLC cells can be effectively distinguished through precise identification of the exosomal protein pattern. And the multiplex characterizations of NSCLC-related exosomes are also achieved by anti-CD63, anti-EGFR and anti-EpCAM modified SPRi array. The limit of detection (LOD) of this SPRi-based biosensor approaches to the level of 10 particles/μL with the help of functionalized gold nanoparticles. Besides, the developed biosensing assay was successfully applied in the determination of exosomes purified from clinical plasma samples. This SPRi biosensing strategy might offer a potential alternative for massive high-throughput screening for NSCLC in clinical specimens.